Evidence map›Paper›PMID 34141836›Full record

ArticleRegenerative therapy2021

Cisplatin induces differentiation in teratomas derived from pluripotent stem cells.

Atsushi Kurata, Masakatsu Takanashi, Shin-Ichiro Ohno, Koji Fujita, Masahiko Kuroda

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Regenerative therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Atsushi KurataDepartment of Molecular Pathology, Tokyo Medical University, 6-1-1, Shinjuku, Shinjuku-ku, Tokyo, Japan.
Masakatsu TakanashiDepartment of Molecular Pathology, Tokyo Medical University, 6-1-1, Shinjuku, Shinjuku-ku, Tokyo, Japan.
Shin-Ichiro OhnoDepartment of Molecular Pathology, Tokyo Medical University, 6-1-1, Shinjuku, Shinjuku-ku, Tokyo, Japan.
Koji FujitaDepartment of Molecular Pathology, Tokyo Medical University, 6-1-1, Shinjuku, Shinjuku-ku, Tokyo, Japan.
Masahiko KurodaDepartment of Molecular Pathology, Tokyo Medical University, 6-1-1, Shinjuku, Shinjuku-ku, Tokyo, Japan.
Tokyo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCurrently, embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) can be induced to differentiate at the cellular level but not to form mature tissues or organs suitable for transplantation. ESCs/iPSCs form immature teratomas after injection into immunodeficient mice. In humans, immature teratomas often transform into fully differentiated mature teratomas after administration of anticancer agents.

methodsWe first investigated the ability of cisplatin to induce changes in mouse ESCs/iPSCs

resultsTreatment of ESC/iPSC cultures with cisplatin for 3 days caused a dose-related decrease in cell numbers without inducing any morphological changes to the cells. ESC/iPSC-derived teratomas showed lower growth rates with a significantly higher mature components ratio in a concentration dependent manner after cisplatin treatment (P < 0.05); however, immunohistochemical analyses demonstrated a significantly reduced PCNA labelling index and an increase in an apoptosis marker on immature neural components (P < 0.05) along with emergence of h-Caldesmon

conclusionsCisplatin has the ability to reduce immature components in ESC/iPSC-derived teratomas, presumably through apoptosis, and also to induce them to differentiate.

Indexed as

ALP, alkaline phosphataseATP4B, ATPase H+/K+ transporting beta subunitCisplatinCR, chemotherapeutic retroconversionDifferentiationDMEM, Dulbecco's modified Eagle's mediumEmbryonic stem cellsESC, embryonic stem cellFCS, fetal calf serumHE, hematoxylin and eosinImmature teratomaInduced pluripotent stem cellsiPSC, induced pluripotent stem cellKSR, knockout serum replacementLIF, leukemia inhibitory factorMEF, mouse embryonic fibroblastPBS, phosphate buffered salinePCNA, proliferating cell nuclear antigenRAG, recombination activating geneRLU, relative light unitsRT, room temperaturessDNA, single stranded DNAα-SMA, α-smooth muscle actin

Identifiers

PMID34141836
PMCPMC8192819
OpenAlexW3169994198

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.